Back to Boston Scientific

Boston Scientific News

BSX

BSX: Wichmann Named Lead Independent Director

Boston Scientific says Wichmann will succeed Ludwig as Lead Independent Director on Jan. 1, 2027.

BSX

BSX: Boston Scientific Names New COO, CFO

Boston Scientific (BSX) promotes Joe Fitzgerald to COO and appoints Mark Bickel as CFO successor to Woodworth. Company updates amid recent cyber incident.

BSX

BSX: Arthur Butcher to Retire Jan 1, 2027

Boston Scientific (BSX) EVP and Group President Arthur C. Butcher will retire effective 1/1/2027. Key investor implications and company context.

BSX

Boston Scientific Lowers 2026 Earnings Guidance

Boston Scientific (BSX) lowers Q3 and full-year 2026 earnings guidance after Aug 26 cybersecurity incident disrupted operations.

BSX

BSX: Global Cybersecurity Incident Disrupts Operations

Boston Scientific (BSX) reports a global cyber incident disrupting IT systems and order processing; investors should watch company disclosures.

BSX

Boston Scientific Approves Global Restructuring

BSX launches a global restructuring on 2026-07-27 to cut costs and support growth amid planned acquisition and refinancing.

BSX

Boston Scientific Secures $11B Credit Facilities

Boston Scientific (BSX) arranges $11B in credit facilities to refinance debt and fund an acquisition. Implications for liquidity, leverage and capital allocation as of 2026-02-26.

BSX

Boston Scientific to Acquire Penumbra (BSX)

Boston Scientific (BSX) announces intent to acquire Penumbra via merger. Read a concise investor-focused summary and context as of 2026-02-26.

BSX

BSX: Boston Scientific Board Expands to 12

Boston Scientific (BSX) expands its board to 12 with two new directors; two directors are scheduled to retire at the 2026 annual meeting.

BSX

Boston Scientific Expands Buyback to $5B

Boston Scientific's board approved a $4B increase to its stock repurchase program, expanding authorization to $5B. Investor-focused context and risks.

BSX

BSX: Director John Sununu to Leave in 2026

Boston Scientific director John Sununu will not seek re-election at the 2026 annual meeting — implications for board succession and investors.

BSX

Boston Scientific (BSX) Completes Key Acquisitions

Boston Scientific (BSX) acquires Nalu Medical and assets from Elutia, bolstering MedSurg and cardiovascular product pipeline and M&A-driven growth strategy.

BSX

BSX Q3 2025: Revenue Beats Guidance

Boston Scientific (BSX) Q3 2025 sales rose 20.3% to $5.065B; EPS $0.75 exceeded forecasts. Read key drivers, segment context, and investor considerations.

BSX

BSX Raises 2025 Earnings Guidance

Boston Scientific (BSX) raises its 2025 sales and EPS outlook. Analysis of drivers, segment exposure (Cardiovascular, MedSurg), risks, and investor implications.

BSX

BSX: Boston Scientific Restructures After Valve Cut

Boston Scientific (BSX) announces restructuring after discontinuing the ACURATE valve system. Analysis of segment impact, risks and strategic implications.

BSX

BSX: FARAPULSE Approved in Japan for Persistent AF

Boston Scientific's FARAPULSE PFA system gains approval in Japan to treat persistent atrial fibrillation, supporting electrophysiology growth and APAC expansion.